Paper Details

  1. Home
  2. Paper Details

Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia.

Author: AndreeffM, BermanE, ClarksonB, CunninghamI, GaynorJ, GeeT, GulatiS, KempinS, LittleC

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

This study examined the treatment of acute lymphoblastic leukemia (ALL) in 250 adults over 20 years using five different chemotherapy regimens. The best outcomes were observed with the L10 and L10M regimens, resulting in the highest rates of long-term remission (over 5 years). Overall, 31% of patients survived long-term, with 35% of those achieving remission remaining relapse-free for over 5 years. While outcomes have improved, the study highlights the challenges of treating relapsed ALL, as long-term survival rates are low after a second or subsequent relapse. The study also emphasizes the need for careful patient selection for bone marrow transplantation to improve outcomes.
Paper Details　
Original Abstract of the Article :
During the past 20 years, we have treated 250 previously untreated adults (greater than age 15 years) with acute lymphoblastic leukemia (ALL) with five successive multidrug protocols: L2, L10, L10M, L17/17M, and L20. The L10 and L10M protocols had the highest percentage of long-term (greater than 5 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-642-74643-7_75

データ提供：米国国立医学図書館（NLM）

Long-Term Follow-Up: A Crucial Step in Treating Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a serious blood cancer, requiring intensive treatment regimens. This study emphasizes the importance of long-term follow-up in evaluating the effectiveness of these treatments in adults. The researchers examined the outcomes of 250 patients with ALL, tracing their progress over many years. They looked for long-term remissions, relapses, and survival rates, hoping to understand the long-term impact of various treatment strategies.

The Significance of Time in Cancer Treatment

The study found that long-term follow-up is crucial in evaluating ALL treatment. The researchers discovered that the disease-free survival rate plateaued after six years, highlighting the importance of extended monitoring for potential relapses.

Navigating the Path to Recovery: Long-Term Follow-Up in Cancer Treatment

This study underscores the need for long-term follow-up in cancer treatment. It's a vital component of ensuring that patients receive the most appropriate care, helping them navigate the long journey towards recovery.

Dr.Camel's Conclusion

The treatment of ALL, like traversing a vast and unforgiving desert, requires a commitment to long-term vigilance. This study reminds us that while a journey may begin with hope, it is the constant monitoring and care that ensures a safe passage to recovery.

Date :
  1. Date Completed 1990-05-24
  2. Date Revised 2019-10-22
Further Info :

Pubmed ID

2182430

DOI: Digital Object Identifier

10.1007/978-3-642-74643-7_75

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.